Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD16A | O95870 | 2/20 | 0.72 |
| ▸ | MGLL | Q99685 | 5/20 | 0.65 |
| ▸ | FAAH | O00519 | 4/20 | 0.65 |
| ▸ | LPL | P06858 | 1/20 | 0.52 |
| ▸ | LIPC | P11150 | 1/20 | 0.52 |
| ▸ | LIPE | Q05469 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044439 | 0.93 | MGLL (0.78) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL2853266 | 0.86 | MGLL (0.64) | ABHD16AMGLLFAAHNPBWR1 | |
| SCHEMBL2235103 | 0.85 | ABHD16A (0.74) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL7044319 | 0.84 | ABHD16A (0.53) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL2233598 | 0.84 | ABHD16A (0.72) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL7046228 | 0.84 | ABHD16A (0.72) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL11620781 | 0.83 | FAAH (0.78) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL6551854 | 0.81 | FAAH (0.74) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL7043932 | 0.81 | LPL (0.56) | ABHD16AMGLLFAAHLPLLIPC | |
| SCHEMBL7578034 | 0.81 | ABHD16A (0.68) | ABHD16AMGLLFAAHLPLLIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299264-B2 | Method for producing oxadiazolinone compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2357167-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | AHR, CYP1B1, AR | ABHD16A 3723/4885MGLL 4777/4885FAAH 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.